UCB is preparing for a changing of the guard. The Belgium-based drugmaker has tapped Jean-Christophe Tellier, who heads up its biopharma brands unit, to take over as CEO beginning next year, replacing current chief Roch Doliveux.
UCB (UCBJF) recently presented data from a study showing the effect of Neupro on cardiovascular measures in patients with restless legs syndrome (RLS).
The double-blind, placebo-controlled study showed reduction in total nocturnal systolic...
(Nasdaq: IMMU),a biopharmaceutical company primarily focused on the development
of monoclonal antibody-based products for the targeted treatment of cancer,
autoimmune and other serious diseases, today reported that UCB...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to UCB SA (UCB-BT):